酸对抗P-选择因介导的血小板-白细胞相互作用:对法国悖论的含义
Chantal C M Appeldoorn1, Arnaud Bonnefoy, Bianca C H Lutters
1Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University, Gorlaeus Laboratories, Leiden, The Netherlands.
红葡萄酒中的多之一酸有效地抑制P-选择素,这是炎症细胞招募的关键分子. 这一发现为酸在预防动脉样硬化的潜在作用提供了机械解释.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 炎症研究 炎症研究
背景情况:
- 这是一个很棒的节目,这是一个很棒的节目.
研究的目的:
- 研究酸 (GA) 对P-选择素活性的影响.
- 探索GA在抗氧化作用之外的动脉保护中的潜在作用.
主要方法:
- 在体外测试测量GA抑制P-选择因子结合物的抑制.
- 动态流量研究评估GA对细胞在剪切应力下滚动的影响.
- 在小鼠模型中的体内显微镜,以评估GA对单细胞-血小板相互作用的影响.
主要成果:
- 酸强烈抑制了P-选择素与其配体的结合.
- 根据GA的剂量,单细胞细胞滚动减少,白细胞滚动速度增加.
- 在体内给药GA损害了单细胞 - 血小板结合体在小鼠中的滚动.
结论:
- 酸对抗P-选择素,为其抗炎和动脉保护作用提供了机制基础.
- GA对P-选择素的抑制为炎症性血管疾病提供了一个新的治疗点.
更多相关视频
09:13Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
相关概念视频
Paracrine Signaling
GPCRs Regulate Adenylyl Cylase Activity
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
